Lyell reports Q4 net loss $52.9M, full-year loss $234.6M; cash $562.7M supports pipeline into 2027

Lyell Immunopharma, Inc.

2023-FY EPS reported -$0.93 revenue$130,000

Net loss $52.9M in Q4 2023 and $234.6M full year; non-GAAP net loss $43.9M Q4 and $177.4M FY.
Revenue $0.1M in FY2023 vs $84.7M in FY2022 due to termination of GSK collaboration in Dec 2022.
Cash $562.7M as of Dec 31, 2023; expected to fund operations into 2027.
Expect initial clinical data from LYL797 CAR T in H1 2024 and LYL845 TIL in H2 2024; LYL845 got FDA Orphan Drug Designation for melanoma.
Appointed Matt Lang as Chief Business Officer; IND submission for LYL119 expected H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $52.9 million.

Period: the fourth quarter and full year ended December 31, 2023
Net income: $52.9 million
Result: reported results

Exact text from the filing

Fourth Quarter and Full Year 2023 Financial Results Lyell reported a net loss of $52.9 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-007579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.